AlphaStocks
5.0
Consider Buy

Cencora, Inc. (COR)

As of Sep 20, 2026, Cencora, Inc. (COR) scores 5.0/10 on AlphaStocks' five-model composite, #113 of 168 Health Care stocks. At $309, COR trades 57% above its model fair value of $197.

Health Care / Health Care Distributors

S&P 500

$308.61

Below average on several measures. Research carefully.

Consider Buy

Score based on 5 of 5 models — high confidence

Data as of Sep 20, 2026

#113out of 168 in Health Care

Is Cencora, Inc. a Good Investment in 2026?

Cencora, Inc. (COR) scores 5.0 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Buffett model rates Cencora, Inc. as Strong. However, the Greenblatt Magic Formula model rates it Caution — Earnings yield 6.8% · ROC 8%. Cencora, Inc. currently trades 57% above its estimated fair value of $197. Cencora, Inc. ranks #113 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E38.8ROE89.1Market Cap60BDiv Yield0.7

Estimated Fair Value

$197.1257% above

Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of 6% may not justify the premium.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Strong

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 3.4 · Stalwart

Greenblatt

Caution

Earnings yield 6.8% · ROC 8%

Frequently Asked Questions

Is Cencora, Inc. (COR) a good investment?
As of Sep 20, 2026, Cencora, Inc. (COR) scores 5.0/10 on AlphaStocks' five-model composite, #113 of 168 Health Care stocks. At $309, COR trades 57% above its model fair value of $197. That score is below average, suggesting caution.
What is Cencora, Inc.'s Piotroski F-Score?
Cencora, Inc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is COR overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $197, COR appears overvalued. The stock currently trades 57% above its estimated fair value. Trading above estimated fair value. P/e of 39x implies high growth expectations. eps growth of 6% may not justify the premium.
How does COR compare to other Health Care stocks?
Cencora, Inc. ranks #113 out of 168 stocks in the Health Care sector, placing it in the top 67% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about COR?
AlphaStocks evaluates COR using five proven investment models. Piotroski: Attractive; Buffett: Strong; Graham: Caution; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.0/10.

Similar Stocks

CAHHSICMCK

Compare COR with

CAH vs CORCOR vs HSICCOR vs MCKCOR vs PARR

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer